Big Pharma player Sanofi has changed its top leader but CEO Olivier Brandicourt has been unable to keep the drugmaker’s trajectory from heading down. Sanofi is…

Today is the first day for England’s drug cost watchdog to take the reins of the beleaguered Cancer Drugs Fund and the moment it took over, NICE faced…

Vertex has pumped up the launch for slow-starting cystic fibrosis med Orkambi--but it took some serious spending to do it.

Would AstraZeneca really find itself contending with another megamerger offer, this time from Novartis? That’s the speculation on the street, despite signs…

Bristol-Myers Squibb came through in Q2 on both the sales and earnings fronts and raised guidance once again. But it wasn’t Opdivo and the usual suspects…

It’s a silver-lining quarter for AstraZeneca. Second-quarter sales slid--but not as far as market watchers expected--and new cancer meds, diabetes drugs and…

As England's cost watchdogs were weighing Gilead’s evidence and pricing for its hep C drugs, the country’s National Health Service was maneuvering to…

With billions in sales under biosimilar threat and facing investor pressure to make M&A moves, Amgen on Wednesday posted revenue and earnings beats for the…

The FDA stepped up warnings on antibiotics like Johnson & Johnson’s Levaquin, adding long-term risks to the drugs’ current black box. The drugs'…